CHICAGO, June  12, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (&#34;Cosmos Health&#34; or the &#34;Company&#34;) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its

COSM

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines

Cosmos Health secures 253,657-unit Cana order, signaling near-term revenue visibility

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>CHICAGO, June  12, 2026  (GLOBE NEWSWIRE) -- Cosmos Health Inc. (&amp;#34;Cosmos Health&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Cosmos Health announced Cana Laboratories received new contract manufacturing orders totaling 253,657 units from Nassington and Verisfield for multiple medicines. The deal highlights demand for Cana&#039;s contract manufacturing and Cosmos&#039; vertically integrated platform with EU GMP/EMA-certified facilities. The catalyst may lift near-term revenue visibility and investor sentiment as orders convert to revenue in coming quarters.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Cana Labs wins a 253,657-unit contract from Nassington and Verisfield.</li><li>Manufactures Gritse, Fungofort, Paco-4, dexamethasone, and Foproct products.</li><li>CEO cites demand for Cana and the strength of Cosmos&#039; vertical platform.</li><li>Cosmos Health emphasizes EMA/GMP-certified EU manufacturing and global expansion.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Cosmos Health Inc. (COSM)</strong>: Subject of the release; orders via Cana may lift near-term revenue and valuation.</li><li><strong>Nassington</strong>: Private customer; contract win signals demand for Cana&#039;s manufacturing capabilities.</li><li><strong>Verisfield</strong>: Private customer; contract win signals demand for Cana&#039;s manufacturing capabilities.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article reports an operational contract win for Cana Laboratories, reinforcing Cosmos&#039; integrated manufacturing model and potentially improving near-term revenue visibility.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Cana orders total 253,657 units across multiple products, signaling immediate revenue visibility.</li><li>Products include Gritse, Gritse Forte, Fungofort, Paco-4, dexamethasone, and Foproct.</li><li>Cana operates under EU GMP/ EMA certification, supporting scalable manufacturing.</li><li>Private customers Nassington and Verisfield drive near-term execution without public-listed implications.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of release: June 12, 2026.</li><li>Combined orders: 253,657 units across medicines and pharma products.</li><li>Products listed: Gritse 0.4 mg/ml; Gritse Forte 2 mg/ml and 4 mg/ml; Fungofort; Paco-4; dexamethasone formulations; Foproct.</li><li>Cana Laboratories S.A. is a wholly-owned Cosmos subsidiary.</li><li>Cosmos Health (COSM) emphasizes EMA/GMP-certified manufacturing and EU/UK operations.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>COSM could see near-term upside on the Cana contract; monitor revenue timing and margins over the next 1–2 quarters.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>CHICAGO, June  12, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gx02EXLKkkeChsGKKMvsp5ErVq84qHu0WL149mL4ExHNdBHGrFW3GkKmYdC8s-DMLLKDg5Fy4cN_mE9NItZFlzEx8wyi97GJTEUEagB1b3Y=" rel="nofollow" target="_blank"><strong><u>Cosmos Health Inc.</u></strong></a><strong> (&#34;Cosmos Health&#34; or the "Company") </strong><a href="https://www.globenewswire.com/Tracker?data=YtQ3vboGnvqP7-764HPKxZ2ZDpzxd9O2xocOIFVMdx5GDxhiip15JI8RyAlThfkpEHDhVyGX0_8VC0sOb9xmJ96yykJQ_JK14qqs9bStkgM=" rel="nofollow" target="_blank"><strong><u>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>)</u></strong></a>, a diversified, vertically integrated global healthcare group, today announced that its wholly-owned subsidiary, Cana Laboratories (&#34;Cana&#34;), has received new contract manufacturing orders from Nassington and Verisfield for a combined 253,657 units across a range of medicines and other pharmaceutical products.</p>  <p>Under the orders, Cana will manufacture Gritse oral solution 0.4 mg/ml (bottle x 150 ml); Gritse forte oral solution 2 mg/ml (bottle x 50 ml); Gritse forte oral solution 4 mg/ml (bottle x 50 ml); Fungofort cutaneous spray, solution (30 ml); Paco-4 tablets (250+250+65+35 mg); dexamethasone 2 mg/5 ml, in 50 ml and 150 ml bottle and oral solution presentations; and Foproct rectal cream (1 + 1.5%).</p>  <p><strong>Greg Siokas, CEO of Cosmos Health, stated: </strong>&#34;These orders reflect the demand for Cana&#39;s contract manufacturing capabilities and the strength of our vertically integrated platform. By deepening our relationships with established pharmaceutical partners across a broad range of products, we continue to build a diversified manufacturing business that supports long-term value creation for our shareholders."</p>  <p align="justify"><strong>About Cosmos Health Inc.<br></br></strong>Cosmos Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life&#xAE;, Mediterranation&#xAE;, bio-bebe&#xAE;, C-Sept&#xAE; and C-Scrub&#xAE;. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&amp;D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&amp;D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at <a href="https://www.globenewswire.com/Tracker?data=MO9nqd_nCu4-VSjKT7tcKOHL-FeWcyWSt7VBF333nRlKXF1Yx8NxGZG-RpF2VMPLW98FCg90-cJu3wCFNCodBNEhAHzq1gr3ME-T2BGs11NYG5khsL8TMOGIVD9QHXw3" rel="nofollow" target="_blank"><u>www.cosmoshealthinc.com</u></a>, <a href="https://www.globenewswire.com/Tracker?data=yRwA8MHmQtVCLLiuRWaA8SkIbgQLHUOzbwTzJebA23dK9Gqz-zPNknOElK65FOr15a-dBvFirSxF4ah-5an6Lsz0IZOIaVqZfoXkjkvy6PE=" rel="nofollow" target="_blank"><u>www.skypremiumlife.com</u></a>, <a href="https://www.globenewswire.com/Tracker?data=MO9nqd_nCu4-VSjKT7tcKFafDBY5F2qil-xIpyWek0lE_agDS9JbkzgkHFbj4vqw6jXl9g-LpTE89jpZzC1gcA==" rel="nofollow" target="_blank"><u>www.cana.gr</u></a>, <a href="https://www.globenewswire.com/Tracker?data=q_SI6o5wXnpstQ80Fp2uqb98lkNv7eGqmJ_7HlUhg_6Op5_PIb_kgwBzhqlFVYt6dE9J1mPQyILegqrcvN4GMSegw4A1oW0uGNzfh6QR0oQ=" rel="nofollow" target="_blank"><u>www.zipdoctor.co</u></a>, <a href="https://www.globenewswire.com/Tracker?data=MO9nqd_nCu4-VSjKT7tcKGNPo2NFEnRSipWDAm_oTjwS27lZFEUt9tU1mB2Vc6kGsnHyeNjfmL4G8O3ZiuW3WAX5o5cHhw4ypEmwrjvShe0=" rel="nofollow" target="_blank"><u>www.cloudscreen.gr</u></a>, as well as <a href="https://www.globenewswire.com/Tracker?data=GiyRYqG6hpP66cBMB43YDAvOhIXVMhHRJujDRMw1D4VKyOvuOqdTTNs21MvTzP6LK32VjGTECj92dGHNgFCOEkfcYNc5f_ZNLnqOJnwCbY3hoC8yx6x7_N3cQj7-KUrQ" rel="nofollow" target="_blank"><u>LinkedIn</u></a> and <a href="https://www.globenewswire.com/Tracker?data=1KJWmHHyg7W_CSepjIWEXVk13v2_1a3lbNUz40KqudqvMDILmCfiYhQ1K8yPcjXwlwjs1Zw491qNZeZTjI7oAX7js2gKKVs3ZUnVtYhb4Zc=" rel="nofollow" target="_blank"><u>X</u></a>.</p>  <p align="justify"><strong>Forward-Looking Statements</strong><br></br>With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (<a href="https://www.globenewswire.com/Tracker?data=yRwA8MHmQtVCLLiuRWaA8VxPawS20BgE-EYis-DQOVfoPqH59tYAnDaHA1NWAIsg0cEvTv8Y0JlYzRVGodgk9A==" rel="nofollow" target="_blank"><u>www.sec.gov</u></a>). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.</p>  <p align="justify"><strong>Investor Relations Contact:</strong><br></br>BDG Communications<br></br><a href="https://www.globenewswire.com/Tracker?data=BI9wdu1sM_UqPwk3sttae6pg61jcrjIAYP_ZznA2dxKQE1jSPz4It9SeN4VoF2flsUa-DWeNNQhucm3ivX9LYYyAhhSm9rSMlf25wTNNvHUOOxZSmf8ovkRWD-2FlZ8M" rel="nofollow" target="_blank">cosm@bdgcommunications.com</a> </p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc0NjM3NiM3NjU5ODc3IzIyOTgwOTQ="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MmUxZmM2YjYtMjhjYS00MzNkLWE2N2EtMmI2MWRmNTE5NmIwLTEzMDk2NDQtMjAyNi0wNi0xMi1lbg==/tiny/Cosmos-Health-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4"><img src="https://ml.globenewswire.com/media/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4/small/cosmos-png.png" border="0" width="150" height="78" alt="Primary Logo"></img></a></p>

Cosmos Health announced Cana Laboratories received new contract manufacturing orders totaling 253,657 units from Nassington and Verisfield for multiple medicines. The deal highlights demand for Cana's contract manufacturing and Cosmos' vertically integrated platform with EU GMP/EMA-certified facilities. The catalyst may lift near-term revenue visibility and investor sentiment as orders convert to revenue in coming quarters.

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News